What’s Propelling Plx Pharma Inc (NASDAQ:PLXP) After Higher Shorts Reported?

August 10, 2018 - By Robert Reynolds

The stock of Plx Pharma Inc (NASDAQ:PLXP) registered an increase of 146.58% in short interest. PLXP’s total short interest was 36,000 shares in August as published by FINRA. Its up 146.58% from 14,600 shares, reported previously. With 20,200 shares average volume, it will take short sellers 2 days to cover their PLXP’s short positions. The short interest to Plx Pharma Inc’s float is 0.47%.

The stock decreased 5.41% or $0.2 during the last trading session, reaching $3.5. About 4,416 shares traded or 15.09% up from the average. PLx Pharma Inc. (NASDAQ:PLXP) has declined 26.38% since August 10, 2017 and is downtrending. It has underperformed by 38.95% the S&P500.

PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing nonsteroidal anti-inflammatory drugs and other pharmaceutical agents. The company has market cap of $30.56 million. The Company’s lead product is Aspertec 325 mg, a novel formulation of aspirin that uses the PLxGuard delivery system to reduce acute gastrointestinal side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. It currently has negative earnings. The companyÂ’s product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation; and Aspertec 81 mg, a novel formulation of aspirin, which is in late-stage development.

Another recent and important PLx Pharma Inc. (NASDAQ:PLXP) news was published by Globenewswire.com which published an article titled: “PLx Pharma Inc. Reports Second Quarter 2018 Results” on August 10, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.